FDA Lifts Hold on Concert Pharma's Study Testing Hair Loss Drug FDA Lifts Hold on Concert Pharma's Study Testing Hair Loss Drug
Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Dermatology News Source Type: news
FDA lifts hold on Concert Pharma's study testing hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - July 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA lifts hold on Concert Pharma's hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - July 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Alopecia Areata: Current Practices vs. New Directions Alopecia Areata: Current Practices vs. New Directions
Many treatments for alopecia areata are available, but none have been validated or are FDA approved. This paper reviews therapies currently under investigation and novel modalities which show promise.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
FDA Places Clinical Hold on Concert Pharma's Hair Loss Drug FDA Places Clinical Hold on Concert Pharma's Hair Loss Drug
Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a mid-stage trial testing the company ' s drug to treat alopecia areata.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 18, 2017 Category: Allergy & Immunology Tags: Pharmacist News Source Type: news
FDA places clinical hold on Concert Pharma's hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Concert Pharmaceuticals commences Phase IIa trial to study CTP-543 in alopecia areata
US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news
How Should Physicians Respond to Latest Alopecia Research? How Should Physicians Respond to Latest Alopecia Research?
Dr Lipper discusses evidence and strategy for treating patients with alopecia areata.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 17, 2017 Category: Dermatology Tags: Dermatology Viewpoint Source Type: news
Suicide no more likely in men on 5 α-reductase inhibitors
Raised relative risk of self-harm and depression in first 18 months, but small absolute risk Related items fromOnMedica Keeping our focus on suicide prevention Alopecia areata Male baldness raises risk of coronary heart disease Thousands with BPH will benefit from new treatment (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 20, 2017 Category: UK Health Source Type: news
New treatment option shows promise for skin and hair conditions
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients ’ quality of life and overall health. An emerging treatment option, however, could provide effective therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 3, 2017 Category: Science Source Type: news
Study defines global burden of skin disease
(University of Colorado Anschutz Medical Campus) A study published today in JAMA Dermatology combines the prevalence of skin diseases around the world with their likelihood of creating disability across the lifespan to define the following 10 most challenging conditions (arranged in order of decreasing 'disability-adjusted life years'): dermatitis, acne, hives, psoriasis, viral skin diseases, fungal skin diseases, scabies, melanoma, pyoderma, cellulitis, non-melanoma skin cancer, decubitus ulcer, and alopecia areata. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2017 Category: Cancer & Oncology Source Type: news
Tofacitinib Shows Promise for Treating Severe Alopecia Areata Tofacitinib Shows Promise for Treating Severe Alopecia Areata
The Janus kinase (JAK) inhibitor tofacitinib shows promise for treating severe alopecia areata and its variants in adults and adolescents, according to two retrospective studies.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 2, 2016 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Drug restores hair growth in patients with alopecia areata
(Columbia University Medical Center) Seventy-five percent of patients with moderate to severe alopecia areata -- an autoimmune disease that causes patchy, and less frequently, total hair loss -- had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2016 Category: Biology Source Type: news
JAK Inhibitor Drugs Show Promise in Alopecia Areata JAK Inhibitor Drugs Show Promise in Alopecia Areata
Two different JAK inhibitor drugs, ruxolitinib and tofacitinib, have shown promise as a treatment for alopecia areata in small clinical trials.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Drug shows promise for hair loss condition
Researchers say a bone marrow drug called Ruxolitinib could help patients regrow hair lost due to the autoimmune condition alopecia areata. WCBS-TV's Dr. Max Gomez reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 26, 2016 Category: Consumer Health News Source Type: news
